Visual Atlas · Cluster companion · 10

Evidence per condition

The condition map separates observational reports, controlled microdosing results, and full-dose clinical research. No condition has a universally established consumer microdosing protocol or response timeline.

90-second quick read · deeper research available

Need the deeper research library?

This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.

Explore the condition-by-condition research →Browse related 90-second reads →

MixedControlled microdose

SeparateFull-dose trials

NoneUniversal timeline

In brief

Observational studies contain positive reports, while placebo-controlled studies often find smaller, mixed, or null effects. Full-dose trials for depression, serious-illness distress, or addiction are important but cannot be transferred directly to self-directed microdosing.

Visual walkthrough

Cover: what microdosing actually helps with — the evidence tier per condition.

The conditions: anxiety, depression, ADHD, PTSD, focus, and creativity, each with a different evidence tier.

Reported versus studied: the most reported benefits are not always the best studied — the gap matters.

Slide distinguishing frequent anxiety-related self-reports from mixed controlled microdosing evidence and separate full-dose trials.

Slide showing a community-reported timeline that has not been established as a universal response window.

Closing slide encouraging evidence-aware tracking without treating a four-week period as a validated protocol.

1 / 6

Swipe or tap the arrows to move through 6 slides

Evidence tier, condition by condition

Anxiety

Observational reports; placebo-controlled findings do not establish treatment.

Depression

Full-dose trials are separate; microdosing findings remain mixed.

ADHD & focus

No established ADHD treatment or reliable cognitive-enhancement effect.

Addiction

Full-dose clinical studies do not validate a microdosing protocol.

Chronic pain

No established chronic-pain treatment effect from microdosing.

Cluster headaches

Reports and small studies do not establish a universal protocol.

Creativity

Controlled work does not show a dependable creativity benefit.

End-of-life distress

The clinical evidence uses supervised perceptible doses, not microdosing.

Sleep & insomnia

No established insomnia treatment; reported sleep effects vary.

OCD

No established microdosing treatment evidence.

PTSD

MDMA research is a different substance and does not prove psilocybin microdosing.

Stress & burnout

Self-reports exist; controlled condition-specific evidence is insufficient.

What the data shows — and how strong it is

How to read the evidence

Controlled microdose studiesObservational associationsFull-dose clinical trialsAnecdote or insufficient data

Verdict

Condition-specific microdosing benefits, schedules, and response timelines are not established. Full-dose clinical findings must remain separate.

Common questions

Answered directly

Q · 01

Does anxiety have “strong” microdosing evidence?

No. Anxiety is frequently reported observationally, but controlled microdosing results remain mixed.

Q · 02

Does depression research prove microdosing works?

No. Stronger depression trials generally use supervised perceptible doses with psychological support.

Q · 03

What does a personal tracking pattern prove?

It can describe an individual observation, not establish causation or a clinical treatment effect.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →

← PreviousPsilocybin vs others Atlas →All 17 topics